Glioblastoma (GBM) remains the most aggressive and therapeutically challenging primary brain tumor and is characterized by strong heterogeneity, rapid progression, and poor clinical outcomes. Accumulating evidence indicates that the immune-angiogenic axis is a... ...

请注册登录后继续浏览